Objectives
The Scottish Medicines Consortium (SMC) is part of Healthcare Improvement Scotland. We advise the 14 NHS boards in NHSScotland on the clinical and cost effectiveness of all new medicines, based on early health technology assessment (HTA) of a submission from the sponsor pharmaceutical company.
In 2013, the Scottish Government conducted a review on patient access to new medicines. 1,2 As a consequence, SMC was asked to implement a series of recommendations to increase transparency, give patients and their representatives a greater role, and increase access to new medicines. We outline here the changes made and their impact to date.
Methods
The key changes implemented were as follows:
• All SMC meetings held in public.
• New, more flexible processes for the evaluation of medicines used at the end of life and for very rare conditions. This includes the option of a Patient and Clinician Engagement (PACE) meeting for end of life or orphan medicines. 3
• A new framework for the assessment of ultraorphan medicines. Taking a cost-consequence analysis approach, this considers the nature of the condition, impact of the new technology, value for money, impact beyond direct health benefits and on specialist services, and costs to the NHS and Personal Social Services.
• Strengthened patient and public involvement in our processes.
• Sponsor pharmaceutical company representatives participate in SMC meetings, in order to enhance industry engagement and understanding of how SMC reaches decisions.
Conclusions
We have worked closely with key stakeholders, including patient groups, clinicians and the pharmaceutical industry, to introduce these changes. So far, experience suggests that we are meeting the desired objectives of increasing transparency and giving patients and their representatives a stronger voice in the decision-making process. Our analyses of data from the first year since the PACE process was introduced shows an increased acceptance rate for end of life and orphan medicines. We will continue to develop and improve these changes over time. 
Patient and clinician engagement process
The aim of the PACE process is to explore the added benefits of the medicine, from both patient/carer and clinician perspectives, that may not be fully captured within the conventional clinical and economic case. 3
The PACE meeting involves a round table discussion with patient representatives and healthcare professional experts focusing on how the medicine can:
• add value to the patient's wellbeing and experience of care (for example, ability to work, impact on quality of life, symptom control)
• add value for the patient's family and/or carers (for example, Impact on family life, impact on the carer's ability to work)
The output from the PACE meeting is a consensus statement, provided to all committee members and presented at the meeting. This has a major influence on the SMC decision.
Historical data on acceptance rates show that over the period 2011-2013, over 50% of both orphan and cancer medicines were not recommended for use. An analysis of decisions on medicines considered under the PACE process during the first full year shows that 23 medicines (70%) have been accepted and 10 (30%) not recommended.
Strengthening the patient and public voice
As this is a key programme of work, we have appointed a Public Involvement Co-ordinator and a Public Involvement Officer to lead it. We have taken several steps to support public understanding of what we do and help patient groups get more involved ( Figure 1 ). End of life -a medicine used to treat a condition at a stage that usually leads to death within 3 years with currently available treatments
Orphan -a medicine with European Medicines Agency (EMA) designated orphan status (conditions affecting fewer than 2,500 people in a population of 5 million) or a medicine to treat an equivalent size of population Ultra-orphan -a medicine used to treat a condition with a prevalence of 1 in 50,000 or less (100 people or less in Scotland)
Since the new staff were appointed in April 2014, there has been a significant increase in the number of patient group submissions received, as a proportion of all full submissions assessed (Figure 2 
